세계의 원발성 담즙성 담관염 시장 보고서(2025년)

Primary Biliary Cholangitis Global Market Report 2025

US $ 4,490 ￦ 6,371,000

PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,490 ￦ 9,209,000

PDF (Site License)

PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,490 ￦ 12,048,000

PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

원발성 담즙성 담관염 시장 규모는 향후 몇 년 동안 강력한 성장세를 보이며 2029년에는 16억 달러 규모로 성장하고, 연평균 9.9%의 성장률을 나타낼 것으로 예상됩니다. 예측 기간 동안의 성장은 바이오마커 연구 확대, 희귀질환 관리에 대한 세계 노력, 임상시험 협력 강화, 환자 중심 의료 접근법, 간 이식 수요 증가 등에 기인하는 것으로 분석됩니다. 예측 기간 동안 주요 동향으로는 바이오마커 연구의 발전, 비침습적 진단 기술의 중요성 증가, 면역조절요법 연구 강화, 인공지능(AI) 통합, 임상시험의 환자 보고 결과, 환자 관리를 위한 원격의료, 병용요법 강화, 섬유증을 타겟으로 한 새로운 치료법 등이 있습니다. 등을 들 수 있습니다.

흡연 증가는 향후 몇 년 동안 원발성 담즙성 담관염 시장의 성장을 견인할 것으로 예상됩니다. 흡연은 담배나 기타 물질의 연소에 의해 발생하는 연기를 흡입하거나 내뿜는 행위입니다. 흡연은 PBC를 포함한 간 질환의 위험 요인으로 인식되고 있으며, 흡연율 증가는 간 관련 문제로 병원을 찾는 사람들이 늘어날 수 있습니다. 일례로, 2023년 7월 캐나다 통계청은 2023년 6월 대비 2.2%의 담배 생산량 증가를 보고했으며, 이에 따라 담배 판매량도 2.6% 증가하여 6월은 5월 대비 14억 개비에 달했다고 보고했습니다. 그 결과, 흡연 증가는 원발성 담즙성 담관염 시장의 성장을 가속할 것으로 예상됩니다.

간암 증가는 향후 원발성 담즙성 담관염 시장의 성장을 가속할 것으로 예상됩니다. 간암은 간세포암으로도 알려져 있으며, 간세포에서 시작되는 암의 일종입니다. 원발성 담즙성 담관염은 담관암, 간세포암 등 다양한 악성 종양의 위험을 증가시키기 때문에 간암에서 중요한 역할을 합니다. 이 질환의 유병률 증가와 잠재적인 합병증은 원발성 담즙성 담관염 시장의 확대에 기여하고 있습니다. 예를 들어, 미국의 대표적인 전문기관인 미국암협회는 2024년 1월 국내 간암 신규 환자 수를 약 41,630명으로 예측하고 있으며, 그 중 남성이 28,000명, 여성이 13,630명일 것으로 예상하고 있습니다. 또한 약 29,840명(남성 19,120명, 여성 10,720명)이 이 질환으로 사망할 것으로 예상됩니다. 결과적으로 간암 환자 증가가 원발성 담즙성 담관염 시장의 성장을 주도하고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나, 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

• 세계 원발성 담즙성 담관염 PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인 및 억제요인)
• 최종 이용 산업 분석
• 세계의 원발성 담즙성 담관염 시장 : 성장률 분석
• 세계의 원발성 담즙성 담관염 시장 실적 : 규모와 성장, 2019-2024
• 세계의 원발성 담즙성 담관염 시장 예측 : 규모와 성장, 2024-2029, 2034F
• 세계 원발성 담즙성 담관염 전체 시장(TAM)

제6장 시장 세분화

• 세계의 원발성 담즙성 담관염 시장 : 치료 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 약물
• 간 이식
• 세계의 원발성 담즙성 담관염 시장 : 진단별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 영상 검사
• Magnetic Resonance Elastography (MRE)
• 자기 공명 담도 췌관 조영검사(MRCP)
• 초음파
• Fibroscan
• 혈액검사
• 콜레스테롤 검사
• 항체 검사
• 간 검사
• 기타 진단
• 세계의 원발성 담즙성 담관염 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 전문 클리닉
• 홈케어
• 기타 최종사용자
• 세계의 원발성 담즙성 담관염 시장 : 약물 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Ursodeoxycholic Acid (UDCA)
• Obeticholic Acid (OCA)
• Fibrates
• 면역 억제제
• 기타 표적치료
• 세계의 원발성 담즙성 담관염 시장 : 간이식 유형별 세분화, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• Orthotopic Liver Transplantation (OLT)
• Living Donor Liver Transplantation
• Hepatobiliary Surgery For Liver Transplant

제7장 지역별/국가별 분석

• 세계의 원발성 담즙성 담관염 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
• 세계의 원발성 담즙성 담관염 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

• 원발성 담즙성 담관염 시장 : 경쟁 구도
• 원발성 담즙성 담관염 시장 : 기업 개요
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

제31장 기타 주요 기업 및 혁신 기업

• AstraZeneca plc
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company
• Amgen Inc.
• Boehringer Ingelheim International GmbH.
• Gilead Sciences Inc.
• Vertex Pharmaceuticals
• Dr. Reddy's Laboratories Ltd.
• Amneal Pharmaceuticals LLC
• Alnylam Pharmaceuticals Inc.
• Ionis Pharmaceuticals Inc.
• Intercept Pharmaceuticals Inc
• Arrowhead Pharmaceuticals Inc.
• CureVac N.V.
• Sangamo Therapeutics Inc.

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장 잠재력이 높은 국가, 부문, 전략

• 원발성 담즙성 담관염 시장(2029년) : 새로운 기회를 제공하는 국가
• 원발성 담즙성 담관염 시장(2029년) : 새로운 기회를 제공하는 부문
• 원발성 담즙성 담관염 시장(2029년) : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제36장 부록

LSH

영문 목차

영문목차

Primary biliary cholangitis (PBC) is a chronic autoimmune liver disease characterized by the progressive inflammation and destruction of the small bile ducts within the liver. This condition can lead to impaired bile flow, liver damage, and various related complications. PBC primarily affects middle-aged women and is often associated with symptoms such as fatigue, itching, and abdominal discomfort.

The main types of treatment for primary biliary cholangitis are drugs and liver transplantation. A drug is any chemical substance that causes a change in an organism's physiology or psychology when consumed, and ursodeoxycholic acid (UDCA) is the standard first-line treatment for PBC. UDCA helps improve liver function, reduce liver inflammation, and slow down disease progression. Primary biliary cholangitis is diagnosed through various imaging tests such as magnetic resonance elastography (MRE), magnetic resonance cholangiopancreatography (MRCP), ultrasound, fibroscan, as well as blood tests including cholesterol tests, antibody tests, and liver function tests. These diagnostic methods are employed by end-users such as specialty clinics, homecare services, and other healthcare facilities.

The primary biliary cholangitis market research report is one of a series of new reports from The Business Research Company that provides primary biliary cholangitis market statistics, including primary biliary cholangitis industry global market size, regional shares, competitors with a primary biliary cholangitis market share, detailed primary biliary cholangitis market segments, market trends and opportunities, and any further data you may need to thrive in the primary biliary cholangitis industry. This primary biliary cholangitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The primary biliary cholangitis market size has grown rapidly in recent years. It will grow from $0.98 billion in 2024 to $1.09 billion in 2025 at a compound annual growth rate (CAGR) of 11.8%. The growth in the historic period can be attributed to increased disease awareness, rising global healthcare expenditure, strategic collaborations in the healthcare sector, focus on patient advocacy, government initiatives for liver health.

The primary biliary cholangitis market size is expected to see strong growth in the next few years. It will grow to $1.6 billion in 2029 at a compound annual growth rate (CAGR) of 9.9%. The growth in the forecast period can be attributed to expansion of biomarker research, global efforts in rare disease management, increased collaboration in clinical trials, patient-centric healthcare approaches, rising demand for liver transplants. Major trends in the forecast period include advancements in biomarker research, growing emphasis on non-invasive diagnostic techniques, research focus on immunomodulatory therapies, integration of artificial intelligence (ai), patient-reported outcomes in clinical trials, telemedicine for patient management, focus on combination therapies, emerging therapies targeting fibrosis.

The anticipated rise in smoking is poised to drive the expansion of the primary biliary cholangitis market in the coming years. Smoking involves the inhalation and exhalation of smoke generated by burning tobacco or other substances. It is a recognized risk factor for liver diseases, including PBC, and elevated smoking rates may result in an increased number of individuals seeking medical attention for liver-related issues. As an illustration, in July 2023, Statistics Canada reported a 2.2% increase in cigarette production compared to June 2023, with a corresponding 2.6% rise in cigarette sales, reaching 1.4 billion units in June compared to May. Consequently, the upswing in smoking is expected to propel the primary biliary cholangitis market's growth.

The rise in liver cancer is expected to drive the growth of the primary biliary cholangitis market in the future. Liver cancer, also known as hepatocellular carcinoma, is a type of cancer that begins in the liver cells. Primary biliary cholangitis plays a significant role in liver cancer due to the increased risk of various malignancies, including cholangiocarcinoma and hepatocellular carcinoma. The growing prevalence of this disease and its potential complications are contributing to the expansion of the primary biliary cholangitis market. For example, in January 2024, the American Cancer Society, a leading professional organization in the U.S., projected approximately 41,630 new cases of liver cancer in the country, with 28,000 cases in men and 13,630 in women. Additionally, about 29,840 individuals (19,120 men and 10,720 women) are expected to die from the disease. As a result, the increase in liver cancer cases is driving the growth of the primary biliary cholangitis market.

Major companies operating in the primary biliary cholangitis market are directing their efforts towards the development of innovative and specialized treatments. This includes the creation of orphan drugs featuring a combination of obeticholic acid (OCA) and bezafibrates for the treatment of primary biliary cholangitis (PBC), aiming to secure market exclusivity. The combination of OCA and bezafibrate, with an orphan drug designation, seeks to provide a more comprehensive and effective approach to managing PBC treatment, potentially enhancing the quality of life for individuals affected by this rare condition. For example, in May 2023, Intercept Pharmaceuticals, Inc., a US-based biopharmaceutical company, obtained orphan drug designation from the FDA for the combination of obeticholic acid (OCA) and bezafibrate as a potential treatment for PBC, a progressive liver disease, with OCA already approved for PBC in the US.

In March 2023, Ipsen SA, a France-based pharmaceutical company, completed the acquisition of Albireo Pharma, Inc. for an undisclosed amount. This strategic move by Ipsen aims to broaden its rare disease portfolio by incorporating novel pipeline prospects, promising therapies for rare cholestatic liver diseases in both children and adults, and leveraging strong scientific and commercial capabilities. Albireo Pharma Inc., a US-based biopharmaceutical company, is actively developing A3907 therapy for primary biliary cholangitis (PBC), contributing to Ipsen's expansion in the rare disease segment.

Major companies operating in the primary biliary cholangitis market report are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck And Co. Inc., Novartis AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company, Amgen Inc., Boehringer Ingelheim International GmbH., Gilead Sciences Inc., Vertex Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Amneal Pharmaceuticals LLC, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intercept Pharmaceuticals Inc., Arrowhead Pharmaceuticals Inc., CureVac N.V., Sangamo Therapeutics Inc., Calliditas Therapeutics AB, NGM Biopharmaceuticals Inc., Bluebird Bio Inc., Intellia Therapeutics Inc., Albireo Pharma Inc., TARGET PharmaSolutions Inc., Genfit S.A., Editas Medicine Inc., CymaBay Therapeutics Inc., Ascletis Pharma Inc.

North America was the largest region in the primary biliary cholangitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary biliary cholangitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the primary biliary cholangitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The primary biliary cholangitis market includes revenues earned by entities by providing services such as psychosocial support services, nutritional guidance services, medical diagnosis, and specialized medical care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The primary biliary cholangitis market also includes sales of products such as fat-soluble vitamins, anti-itch medications, and imaging equipment. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Primary Biliary Cholangitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on primary biliary cholangitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for primary biliary cholangitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The primary biliary cholangitis market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment Type: Drugs; Liver Transplantation
• 2) By Diagnosis: Imaging Tests; Magnetic Resonance Elastography (MRE); Magnetic Resonance Cholangiopancreatography (MRCP); Ultrasound; Fibroscan; Blood Tests; Cholesterol Test; Antibody Tests; Liver Tests; Other Diagnoses
• 3) By End-Users: Specialty Clinics; Homecare; Other End-Users
• Subsegments:
• 1) By Drugs: Ursodeoxycholic Acid (UDCA); Obeticholic Acid (OCA); Fibrates; Immunosuppressive Drugs; Other Targeted Therapies
• 2) By Liver Transplantation: Orthotopic Liver Transplantation (OLT); Living Donor Liver Transplantation; Hepatobiliary Surgery For Liver Transplant
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Merck And Co. Inc.; Novartis AG; Bristol-Myers Squibb Company
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Primary Biliary Cholangitis Market Characteristics

3. Primary Biliary Cholangitis Market Trends And Strategies

4. Primary Biliary Cholangitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Primary Biliary Cholangitis Growth Analysis And Strategic Analysis Framework

• 5.1. Global Primary Biliary Cholangitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Primary Biliary Cholangitis Market Growth Rate Analysis
• 5.4. Global Primary Biliary Cholangitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Primary Biliary Cholangitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Primary Biliary Cholangitis Total Addressable Market (TAM)

6. Primary Biliary Cholangitis Market Segmentation

• 6.1. Global Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Drugs
• Liver Transplantation
• 6.2. Global Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Imaging Tests
• Magnetic Resonance Elastography (MRE)
• Magnetic Resonance Cholangiopancreatography (MRCP)
• Ultrasound
• Fibroscan
• Blood Tests
• Cholesterol Test
• Antibody Tests
• Liver Tests
• Other Diagnoses
• 6.3. Global Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Specialty Clinics
• Homecare
• Other End-Users
• 6.4. Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ursodeoxycholic Acid (UDCA)
• Obeticholic Acid (OCA)
• Fibrates
• Immunosuppressive Drugs
• Other Targeted Therapies
• 6.5. Global Primary Biliary Cholangitis Market, Sub-Segmentation Of Liver Transplantation, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Orthotopic Liver Transplantation (OLT)
• Living Donor Liver Transplantation
• Hepatobiliary Surgery For Liver Transplant

7. Primary Biliary Cholangitis Market Regional And Country Analysis

• 7.1. Global Primary Biliary Cholangitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Primary Biliary Cholangitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Primary Biliary Cholangitis Market

• 8.1. Asia-Pacific Primary Biliary Cholangitis Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Primary Biliary Cholangitis Market

• 9.1. China Primary Biliary Cholangitis Market Overview
• 9.2. China Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Primary Biliary Cholangitis Market

• 10.1. India Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Primary Biliary Cholangitis Market

• 11.1. Japan Primary Biliary Cholangitis Market Overview
• 11.2. Japan Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Primary Biliary Cholangitis Market

• 12.1. Australia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Primary Biliary Cholangitis Market

• 13.1. Indonesia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Primary Biliary Cholangitis Market

• 14.1. South Korea Primary Biliary Cholangitis Market Overview
• 14.2. South Korea Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Primary Biliary Cholangitis Market

• 15.1. Western Europe Primary Biliary Cholangitis Market Overview
• 15.2. Western Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Primary Biliary Cholangitis Market

• 16.1. UK Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Primary Biliary Cholangitis Market

• 17.1. Germany Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Primary Biliary Cholangitis Market

• 18.1. France Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Primary Biliary Cholangitis Market

• 19.1. Italy Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Primary Biliary Cholangitis Market

• 20.1. Spain Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Primary Biliary Cholangitis Market

• 21.1. Eastern Europe Primary Biliary Cholangitis Market Overview
• 21.2. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Primary Biliary Cholangitis Market

• 22.1. Russia Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Primary Biliary Cholangitis Market

• 23.1. North America Primary Biliary Cholangitis Market Overview
• 23.2. North America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Primary Biliary Cholangitis Market

• 24.1. USA Primary Biliary Cholangitis Market Overview
• 24.2. USA Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Primary Biliary Cholangitis Market

• 25.1. Canada Primary Biliary Cholangitis Market Overview
• 25.2. Canada Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Primary Biliary Cholangitis Market

• 26.1. South America Primary Biliary Cholangitis Market Overview
• 26.2. South America Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Primary Biliary Cholangitis Market

• 27.1. Brazil Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Primary Biliary Cholangitis Market

• 28.1. Middle East Primary Biliary Cholangitis Market Overview
• 28.2. Middle East Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Primary Biliary Cholangitis Market

• 29.1. Africa Primary Biliary Cholangitis Market Overview
• 29.2. Africa Primary Biliary Cholangitis Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Primary Biliary Cholangitis Market, Segmentation By Diagnosis, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Primary Biliary Cholangitis Market, Segmentation By End-Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Primary Biliary Cholangitis Market Competitive Landscape And Company Profiles

• 30.1. Primary Biliary Cholangitis Market Competitive Landscape
• 30.2. Primary Biliary Cholangitis Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Primary Biliary Cholangitis Market Other Major And Innovative Companies

• 31.1. AstraZeneca plc
• 31.2. GlaxoSmithKline plc
• 31.3. Takeda Pharmaceutical Company
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH.
• 31.6. Gilead Sciences Inc.
• 31.7. Vertex Pharmaceuticals
• 31.8. Dr. Reddy's Laboratories Ltd.
• 31.9. Amneal Pharmaceuticals LLC
• 31.10. Alnylam Pharmaceuticals Inc.
• 31.11. Ionis Pharmaceuticals Inc.
• 31.12. Intercept Pharmaceuticals Inc
• 31.13. Arrowhead Pharmaceuticals Inc.
• 31.14. CureVac N.V.
• 31.15. Sangamo Therapeutics Inc.

32. Global Primary Biliary Cholangitis Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Primary Biliary Cholangitis Market

34. Recent Developments In The Primary Biliary Cholangitis Market

35. Primary Biliary Cholangitis Market High Potential Countries, Segments and Strategies

• 35.1 Primary Biliary Cholangitis Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Primary Biliary Cholangitis Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Primary Biliary Cholangitis Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer

관련자료